June 10, 2024 — A CABBI research team has used CRISPR/Cas9 gene editing to optimize leaf angle in sugarcane, increasing the amount of sunlight it captures and the amount of biomass it ...

A year later came another major breakthrough, as two groups described 2, 3 a novel gene-editing tool called CRISPR-Cas9 and demonstrated its use in eukaryotic cells. These two reports helped start ...

When the CRISPR Cas9 protein is added to a cell along with a piece of guide RNA, the Cas9 protein hooks up with the guide RNA and then moves along the strands of DNA until it finds and binds to a ...

Cas9, the first Cas protein repurposed for cutting DNA, introduces double-strand breaks that recruit DNA repair machinery. Despite its successes, the CRISPR-Cas9 system has several limitations, ...

Through genome editing using CRISPR/Cas9, researchers stably create euglena mutants that can produce wax esters with improved cold flow, making the esters suitable as feedstock for biofuels.

CRISPR-Cas9 is not the first method available to scientists for modifying DNA; it is by far, however, the easiest to use. With CRISPR-Cas9, the crRNA/tracrRNA sequence or an artificial guide RNA ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and can ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

Casgevy, the first US Food and Drug Administration (FDA)-approved therapy that utilizes CRISPR-Cas9, offers new hope for patients with sickle cell disease. But it comes with a hefty price tag – ...

CRISPR/Cas-initiated HR in mouse embryos will be used to generate founder animals harboring inserted sequence targeted to the ROSA26 locus. The targeting will be done in embryos using microinjection ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $45.20, marking a -0.64% move from the previous day. Amidst the long-running Cas9 patent battle, Editas Medicine has struck a ...